Medical Oncology 🏥 Hospital General Universitario Gregorio Marañón ⎪@myESMO Faculty 🫁 ⎪#endlungcancer #lcsm
Madrid, Spain
- Tweets 24,663
- Following 4,402
- Followers 12,170
- Likes 25,575
Pinned Tweet
🎉 Online first: After positive press release of IMforte trial, our timely published review of the MoA of #lurbinectedin and its implications for combinational therapies in #SCLC, including immunotherapy. #LCSM 🫁
Check it out here 👉aacrjournals.org/mct/article…
8
20
65
10,232
⭐️ Siempre es un placer compartir con los compañeros gallegos esta jornada llena de información, afable, y enriquecedora. Agradecer el cariño y la entrega que ponen los organizadores y las constantes mejoras que introducen cada año @mlazqui Sergio Vázquez. Deseando competir el año que viene por la nécora de plata 🦀 🤣
XI reunión de cáncer de pulmón con mutaciones “driver”. Una tarde oncológica de lujo en Lugo. Gracias un año más a los grandes compañeros de toda España que han venido a compartir su sabiduría acerca del cáncer de pulmón con nosotros. Siempre aprendiendo! Por y para los pacientes
60
Dr. Antonio Calles 🫁🚭 retweeted
XI reunión de cáncer de pulmón con mutaciones “driver”. Una tarde oncológica de lujo en Lugo. Gracias un año más a los grandes compañeros de toda España que han venido a compartir su sabiduría acerca del cáncer de pulmón con nosotros. Siempre aprendiendo! Por y para los pacientes
5
24
718
Dr. Antonio Calles 🫁🚭 retweeted
🫁 The New England Journal of Medicine publica un nuevo trabajo de la IARC que analiza la evidencia sobre el uso del TAC de baja dosis para la detección precoz del cáncer de pulmón en población de riesgo.
🗣️ Bartomeu Massutí, secretario del GECP y jefe del Servicio de Oncología Médica del Hospital General Universitario Doctor Balmis de Alicante, analiza en El Mundo sus principales resultados.
elmundo.es/salud/2026/09/24/…
4
10
747
Dr. Antonio Calles 🫁🚭 retweeted
👏 Realmente orgulloso de ver reconocido el compromiso de toda una institución con el cuidado y tratamiento de las personas con cáncer, un compromiso que sitúa al Hospital Gregorio Marañón entre los 50 mejores hospitales oncológicos del mundo.
Un reconocimiento al trabajo de todos. 🏥🎗️@OjodeThot
1
8
42
4,428
Dr. Antonio Calles 🫁🚭 retweeted
El esfuerzo de tantos grandes profesionales y el asesoramiento de los pacientes, parte de nosotros...
👏 Realmente orgulloso de ver reconocido el compromiso de toda una institución con el cuidado y tratamiento de las personas con cáncer, un compromiso que sitúa al Hospital Gregorio Marañón entre los 50 mejores hospitales oncológicos del mundo.
Un reconocimiento al trabajo de todos. 🏥🎗️@OjodeThot
2
10
693
Dr. Antonio Calles 🫁🚭 retweeted
#WCLC26 was a truly global 🌎 meeting . Where else could you meet lung cancer experts from Spain, Mexico, Colombia, Puerto Rico, Canada and Nepal all in one day.
@AnaVManana @Tony_Calles @RamilaShilpakar @mgonzalezvelMD @JorgeAlatorreA1 Dr Marc de Perrot
6
33
1,578
Dr. Antonio Calles 🫁🚭 retweeted
Exciting news of OS signal of pH-sensitive anti-CTLA4 antibody (presumably allowing “recycling” in TME) vs docetaxel in 2nd line treatment of sqNSCLC
While we will need confirmation in phase 3 but still i’d say:
Go-tistobart, go!
New #lungcancer treatment data from #WCLC26.
Gotistobart improved overall survival compared with docetaxel in people with advanced squamous NSCLC whose cancer had progressed after immunotherapy and chemotherapy.
The larger pivotal stage of the trial is ongoing. #LCSM
1
8
30
3,957
DUMAS: Preoperative nivolumab + chemotherapy in Pancoast tumor, a rare entity with many surgical challenges, lead to impresive 58%pCR, and PFS at 24 months 75%. Eager to see more mature survival results but these results already have clinical implications @gecp_org #WCLC26 #LCSM @IASLC
1
24
48
2,314
Dr. Antonio Calles 🫁🚭 retweeted
ARROS-1: 1L Zidesamtinib in ROS1+
Ph1/2, n=94
✅ORR 94%, CR 15%
✅mPFS NR, 90% 1yr PFS
✅ icRR 100%
✅ Low Gr3+ AE
🤔
Impressive efficacy, better than Repo / Tale
But need longer F/U & Ph3
Better tolerated than most other TKIs
CNS activity ++ 👍
❓sequencing
#WCLC26
2
6
8
1,131
Original Article: Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy (phase 3 TAISHAN-302 trial) nej.md/4xKtvcF
#WCLC26 | @IASLC
ALT This image consists of Kaplan–Meier curves for overall survival in the intention-to-treat population.
ALT This image consists of Kaplan–Meier curves for progression-free survival as assessed by the investigators according to Response Evaluation Criteria in Solid Tumors, version 1.1, in the intention-to-treat population.
1
28
111
33,720
Dr. Antonio Calles 🫁🚭 retweeted
The ROS 👑!
Dr. @alexdrilon at #WCLC26 presents 1L cohort of ARROS-1 trial of zidesamtinib in pts with ROS1 NSCLC. What a waterfall plot. RR 94% with 15% CR. mPFS not reached, PFS at 6m was 96% and at 12m was 90%. Intracranial RR 100%. In 78 pts who did not have brain metastases at baseline, no CNS events occurred to date. These are fantastic outcomes.
7
26
1,824
Dr. Antonio Calles 🫁🚭 retweeted
Great people, meaningful conversations, and another memorable WCLC. 💙
Grateful for the friends and colleagues who make these moments so special #WCLC26
8
61
2,635
Dr. Antonio Calles 🫁🚭 retweeted
DESTINY-Lung04 🔥 #WCLC26. 1L T-DXd significantly improves PFS vs pembro + platinum/pemetrexed in HER2-mutant NSCLC: 14.3 vs 8.3 mo | HR 0.63 (95% CI 0.50–0.79), P<0.0001. IA No OS benefit. Of note considerable ILD (overall 20.8%, 2% Gr 5).@JuliaRotow
#HER2 #NSCLC #LCSM
3
10
637
Dr. Antonio Calles 🫁🚭 retweeted
Dr. Julia Rotow @JuliaRotow presents the DESTINY-Lung-04 data of trastuzumab deruxtecan vs pembro+chemo in 1L HER2 NSCLC at @IASLC #WCLC26.
T-DXd improved PFS and ORR, yet OS benefit is limited with this regimen, likely confounded by access to 2L HER2-directed therapies.
AEs notable with ILD 20.8% (>4% G3+).
Difficult to know how T-DXd will fit in the sequencing of an evolving HER2 landscape with available TKIs zongertinib & sevabertinib.
@lungoncdoc @LUNGevity @LungCancerEu @YoungLungCancer @GO2forLungCancr @StephenVLiu
2
5
11
880
Dr. Antonio Calles 🫁🚭 retweeted
#WCLC26 In DESTINY-Lung04, no OS signal yet. Toxicities led to discontinuation in 16% of both arms. Biggest concern here is the ILD at 20.8% - while most were grade 1/2 and resolved, these are still high rates. This will impact delivery and possibly subsequent therapies...
10
29
3,947
Dr. Antonio Calles 🫁🚭 retweeted
Dr. @JuliaRotow at #WCLC26 with primary results from DESTINY-Lung04: first-line trastuzumab deruxtecan vs platinum + pemetrexed + pembro in advanced HER2 mutant NSCLC. Primary endpoint of PFS favors T-DXd at 14.3 vs 8.3m, HR 0.63 and RR 70% vs 44.5%, DOR 13.7 vs 9.7m, PFS2 22.7 vs 17.3m.
2
25
51
5,060